Xiao Liu

6353644, Mar 5, 2002

May 3, 1999

09/303730

Lujing Cai - Tinton Falls NJ
Weimin Liu - Aberdeen NJ
Xiao Liu - Ocean NJ
Wenye Yang - Ocean NJ

Globespan, Inc. - Red Bank NJ

H04B 110

375350, 708300, 375285

Disclosed is a system and method for signal conditioning and equalization in the time domain, preferably in a discrete multi-tone (DMT) modem. The system preferably includes a processor operating according to operating logic stored on a memory although a dedicated logical circuit may be employed. The operating logic includes logic executing the function of a low pass filter having a predetermined cutoff frequency configured to process a digitized data signal having a first sample rate f , producing a filtered data signal at a second sample rate f. The operating logic further includes logic which executes the function of a time domain equalizer, the time domain equalizer being configured to process the filtered signal to shorten the impulse response of the channel while at the same time, the time domain equalizer down-samples the filtered signal from the second sample rate f , to a third sample rate f for further processing in the frequency domain.

7394089, Jul 1, 2008

Aug 25, 2006

11/467294

James P. Doyle - Bronx NY, US
Bruce G. Elmegreen - Golden Bridge NY, US
Lia Krusin-Elbaum - Dobbs Ferry NY, US
Chung Hon Lam - Peekskill NY, US
Xiao Hu Liu - Briarcliff Manor NY, US
Dennis M. Newns - Yorktown Heights NY, US
Christy S. Tyberg - Mahopac NY, US

International Business Machines Corporation - Armonk NY

H01L 47/00

257 4, 257209, 257529, 257E2917

An electrically re-programmable fuse (eFUSE) device for use in integrated circuit devices includes an elongated heater element, an electrically insulating liner surrounding an outer surface of the elongated heater element, corresponding to a longitudinal axis thereof, leaving opposing ends of the elongated heater element in electrical contact with first and second heater electrodes. A phase change material (PCM) surrounds a portion of an outer surface of the electrically insulating liner, a thermally and electrically insulating layer surrounds an outer surface of the PCM, with first and second fuse electrodes in electrical contact with opposing ends of the PCM. The PCM is encapsulated within the electrically insulating liner, the thermally and electrically insulating layer, and the first and second fuse electrodes.

7491965, Feb 17, 2009

May 28, 2008

12/127994

James P. Doyle - Bronx NY, US
Bruce G. Elmegreen - Golden Bridge NY, US
Lia Krusin-Elbaum - Dobbs Ferry NY, US
Chung Hon Lam - Peekskill NY, US
Xiao Hu Liu - Briarcliff Manor NY, US
Dennis M. Newns - Yorktown Heights NY, US
Christy S. Tyberg - Mahopac NY, US

International Business Machines Corporation - Armonk NY

H01L 47/00

257 4, 257209, 257529, 257E2917

An electrically re-programmable fuse (eFUSE) device for use in integrated circuit devices includes an elongated heater element, an electrically insulating liner surrounding an outer surface of the elongated heater element, corresponding to a longitudinal axis thereof, leaving opposing ends of the elongated heater element in electrical contact with first and second heater electrodes. A phase change material (PCM) surrounds a portion of an outer surface of the electrically insulating liner, a thermally and electrically insulating layer surrounds an outer surface of the PCM, with first and second fuse electrodes in electrical contact with opposing ends of the PCM. The PCM is encapsulated within the electrically insulating liner, the thermally and electrically insulating layer, and the first and second fuse electrodes.

7582670, Sep 1, 2009

Apr 13, 2005

11/104422

Longgui Wang - Flushing NY, US
Xiao Mei Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon K. Mencher - New York NY, US

Natrogen Therapeutics, Inc. - Milwaukee WI

A61K 31/40
A61K 31/404
A61K 31/56

514414, 514415, 514416, 514406, 514171, 51425409, 514570, 514159

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

8394847, Mar 12, 2013

Aug 26, 2009

12/548083

Longgui Wang - Flushing NY, US
Xiao Mei Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon K. Mencher - New York NY, US

Natrogen Therapeutics International, Inc. - New York NY

A01N 43/38
A01N 43/12
A01N 43/06
A61K 31/40
A61K 31/38
A61K 31/105

514414, 514415, 514412, 514443, 514448, 514421

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

8563525, Oct 22, 2013

Dec 20, 2010

12/972908

Longgui Wang - Flushing NY, US
Xiao Mei Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon K. Mencher - New York NY, US

Natrogen Therapeutics International, Inc. - New York NY

A61P 1/00
A61P 25/28
A61P 29/00
A61P 19/02

514 43, 514414

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.

20050154046, Jul 14, 2005

Jan 12, 2004

10/754547

Longgui Wang - Flushing NY, US
Xiao Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon Mencher - New York NY, US
James McCarron - New York NY, US

A61K031/404

514414000

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

20120070518, Mar 22, 2012

Sep 21, 2011

13/239230

Longgui Wang - Flushing NY, US
Xiao Mei Liu - Flushing NY, US
Simon K. Mencher - New York NY, US

NATROGEN THERAPEUTICS INTERNATIONAL, INC. - New York NY

A61K 36/886
A61K 36/00
A61P 17/06
A61K 31/404

424744, 514414, 424725

The present invention is directed to topical compositions and methods for topically treating psoriasis comprising meisoindigo as an active ingredient. The topical compositions preferably further comprise skin penetration enhancers, pharmaceutical surfactants and solubility enhancers, oil phase components, aqueous phase components, emulsifiers, moisturizers, antioxidants, vitamins, lubricants, herbal extracts, preservatives, and other ingredients. In addition to meisoindigo, the compositions may comprise other agents commonly used to topically treat psoriasis. The disclosed methods have been demonstrated to effectually treat moderate and severe forms of psoriasis to a degree similar to a potent corticosteroid without side effects. Preferably, the method involves topical application of the disclosed compositions to affected epidermal areas twice a day. In addition, the disclosed methods may be used in conjunction with other common therapies in the treatment of psoriasis.